331 related articles for article (PubMed ID: 9698286)
41. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans.
Zhang D; He K; Raghavan N; Wang L; Mitroka J; Maxwell BD; Knabb RM; Frost C; Schuster A; Hao F; Gu Z; Humphreys WG; Grossman SJ
Drug Metab Dispos; 2009 Aug; 37(8):1738-48. PubMed ID: 19420130
[TBL] [Abstract][Full Text] [Related]
42. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans.
Weinz C; Schwarz T; Kubitza D; Mueck W; Lang D
Drug Metab Dispos; 2009 May; 37(5):1056-64. PubMed ID: 19196845
[TBL] [Abstract][Full Text] [Related]
43. Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis.
Langdon G; Wilkins JJ; Smith PJ; McIlleron H
Int J Tuberc Lung Dis; 2004 Jul; 8(7):862-7. PubMed ID: 15260278
[TBL] [Abstract][Full Text] [Related]
44. Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans.
He H; Tran P; Yin H; Smith H; Batard Y; Wang L; Einolf H; Gu H; Mangold JB; Fischer V; Howard D
Drug Metab Dispos; 2009 Mar; 37(3):536-44. PubMed ID: 19074975
[TBL] [Abstract][Full Text] [Related]
45. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers.
Waldmeier F; Glaenzel U; Wirz B; Oberer L; Schmid D; Seiberling M; Valencia J; Riviere GJ; End P; Vaidyanathan S
Drug Metab Dispos; 2007 Aug; 35(8):1418-28. PubMed ID: 17510248
[TBL] [Abstract][Full Text] [Related]
46. Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs.
Yamaguchi T; Nakajima Y; Mizobuchi M; Inazawa K; Kanazu T; Kadono K; Ohkawa T; Iwatani K
Arzneimittelforschung; 1998 Oct; 48(10):995-1006. PubMed ID: 9825117
[TBL] [Abstract][Full Text] [Related]
47. Excretion and metabolism of trovafloxacin in humans.
Dalvie DK; Khosla N; Vincent J
Drug Metab Dispos; 1997 Apr; 25(4):423-7. PubMed ID: 9107540
[TBL] [Abstract][Full Text] [Related]
48. Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients.
Clive S; Woo MM; Nydam T; Kelly L; Squier M; Kagan M
Cancer Chemother Pharmacol; 2012 Oct; 70(4):513-22. PubMed ID: 22864948
[TBL] [Abstract][Full Text] [Related]
49. Disposition of [14C]acitretin in humans following oral administration.
Rubio F; Jensen BK; Henderson L; Garland WA; Szuna A; Town C
Drug Metab Dispos; 1994; 22(2):211-5. PubMed ID: 8013276
[TBL] [Abstract][Full Text] [Related]
50. A phase I, open-label, mass balance study of [(14)C] dacomitinib (PF-00299804) in healthy male volunteers.
Bello CL; Smith E; Ruiz-Garcia A; Ni G; Alvey C; Loi CM
Cancer Chemother Pharmacol; 2013 Aug; 72(2):379-85. PubMed ID: 23760812
[TBL] [Abstract][Full Text] [Related]
51. Metabolism and excretion of [14C] febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, in healthy male subjects.
Grabowski BA; Khosravan R; Vernillet L; Mulford DJ
J Clin Pharmacol; 2011 Feb; 51(2):189-201. PubMed ID: 20354234
[TBL] [Abstract][Full Text] [Related]
52. Pharmacokinetics of the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB3717) in the mouse.
Newell DR; Alison DL; Calvert AH; Harrap KR; Jarman M; Jones TR; Manteuffel-Cymborowska M; O'Connor P
Cancer Treat Rep; 1986 Aug; 70(8):971-9. PubMed ID: 3731153
[TBL] [Abstract][Full Text] [Related]
53. A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry.
Graham RA; Lum BL; Morrison G; Chang I; Jorga K; Dean B; Shin YG; Yue Q; Mulder T; Malhi V; Xie M; Low JA; Hop CE
Drug Metab Dispos; 2011 Aug; 39(8):1460-7. PubMed ID: 21602311
[TBL] [Abstract][Full Text] [Related]
54. Pharmacokinetics, absolute bioavailability, and disposition of [14C]nefazodone in humans.
Barbhaiya RH; Dandekar KA; Greene DS
Drug Metab Dispos; 1996 Jan; 24(1):91-5. PubMed ID: 8825195
[TBL] [Abstract][Full Text] [Related]
55. Biotransformation of pravastatin sodium in humans.
Everett DW; Chando TJ; Didonato GC; Singhvi SM; Pan HY; Weinstein SH
Drug Metab Dispos; 1991; 19(4):740-8. PubMed ID: 1680649
[TBL] [Abstract][Full Text] [Related]
56. Mass Balance and Metabolic Pathways of Eliapixant, a P2X3 Receptor Antagonist, in Healthy Male Volunteers.
Reif S; Schultze-Mosgau MH; Engelen A; Piel I; Denner K; Roffel A; Tiessen R; Klein S; Francke K; Rottmann A
Eur J Drug Metab Pharmacokinet; 2024 Jan; 49(1):71-85. PubMed ID: 38044419
[TBL] [Abstract][Full Text] [Related]
57. Human metabolism of dolasetron mesylate, a 5-HT3 receptor antagonist.
Reith MK; Sproles GD; Cheng LK
Drug Metab Dispos; 1995 Aug; 23(8):806-12. PubMed ID: 7493546
[TBL] [Abstract][Full Text] [Related]
58. The metabolism and disposition of 14C-fenofibrate in human volunteers.
Weil A; Caldwell J; Strolin-Benedetti M
Drug Metab Dispos; 1990; 18(1):115-20. PubMed ID: 1970770
[TBL] [Abstract][Full Text] [Related]
59. Metabolism and excretion of RWJ-333369 [1,2-ethanediol, 1-(2-chlorophenyl)-, 2-carbamate, (S)-] in mice, rats, rabbits, and dogs.
Mamidi RN; Mannens G; Annaert P; Hendrickx J; Goris I; Bockx M; Janssen CG; Kao M; Kelley MF; Meuldermans W
Drug Metab Dispos; 2007 Apr; 35(4):566-75. PubMed ID: 17220243
[TBL] [Abstract][Full Text] [Related]
60. The disposition and metabolic fate of 14C-meropenem in man.
Harrison MP; Haworth SJ; Moss SR; Wilkinson DM; Featherstone A
Xenobiotica; 1993 Nov; 23(11):1311-23. PubMed ID: 8310714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
